secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001104659-23-027680
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics licenses AJ201 from AnnJi for SBMA; upfront $3M cash + stock
--------------------------------------------------------------------------------

- Upfront cash license fee of $3M ($2M within 60 days, $1M within 180 days).
- Issues 831,618 shares initially; up to 276,652 more on 8th patient enrollment in Phase 1b/2a.
- Milestone payments up to ~$165M based on net sales; royalties mid-single to low double digits.
- AJ201 is in Phase 1b/2a for spinal and bulbar muscular atrophy (Kennedy's Disease); has Orphan Drug Designation.
- Exclusive license covers U.S., Canada, EU, UK, Israel for all oral forms except alopecia and Alzheimer's.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465923027680/0001104659-23-027680-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465923027680/tm238198d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-027680

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer